Lytix 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   3 Trials   74 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lytixar (LTX-109) / Lytix
NCT05889351 / 2022-001938-11: Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Completed
2a
27
Europe
Vehicle gel, 4 + 4 applications or 4 + 2 applications, LTX-109 3% gel, 4 + 4 applications, LTX-109 3% gel, 4 + 2 applications
Pharma Holdings AS, CTC Clinical Trial Consultants AB
Nasal Decolonization of Staphylococcus Aureus
10/22
10/22
2020-000042-34: Proof of concept-studie av LTX-109 som effektiv behandling mot hidrosadenitt (svettekjertelbetennelse)

Not yet recruiting
2
12
Europe
LTX-109
Hidradenitis suppurativa, Hurley stage I-III, Hidradenitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT04854928 / 2021-000455-39: Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

Recruiting
2
60
Europe
LTX-109 gel, 3%, Placebo gel
Pharma Holdings AS, CTC Clinical Trial Consultants AB
COVID-19
02/22
05/22
2022-001938-11: A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus

Not yet recruiting
2
27
Europe
LTX-109 Hydrogel 3% w/w, Gel
Pharma Holdings AS, Pharma Holdings AS
Eradication of Staphylococcus aureus from the nose., Bacterial eradication from the nose., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
Oncopore (ruxotemitide) / Verrica
ATLAS-IT-04, NCT03725605 / 2017-002877-20: LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma

Completed
2
6
Europe
LTX-315 and TILs
Lytix Biopharma AS, Herlev Hospital
Soft Tissue Sarcoma
07/21
10/21
VP-315-201, NCT05188729: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Completed
2
92
US
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Verrica Pharmaceuticals Inc., Instat Clinical Research, HeartcoR Solutions, Myonex, Vial Health Technology, Inc, OncoBay Clinical, Q2 Solutions, Canfield Scientific, Veristat
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
04/24
04/24
NeoLIPA, NCT06651151: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

Recruiting
2
27
Europe
LTX-315 + pembrolizumab
Oslo University Hospital, Lytix Biopharma AS
Melanoma Stage IIIB-IV
05/26
05/31
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
DTT-304 / Lytix
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lytixar (LTX-109) / Lytix
NCT05889351 / 2022-001938-11: Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Completed
2a
27
Europe
Vehicle gel, 4 + 4 applications or 4 + 2 applications, LTX-109 3% gel, 4 + 4 applications, LTX-109 3% gel, 4 + 2 applications
Pharma Holdings AS, CTC Clinical Trial Consultants AB
Nasal Decolonization of Staphylococcus Aureus
10/22
10/22
2020-000042-34: Proof of concept-studie av LTX-109 som effektiv behandling mot hidrosadenitt (svettekjertelbetennelse)

Not yet recruiting
2
12
Europe
LTX-109
Hidradenitis suppurativa, Hurley stage I-III, Hidradenitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT04854928 / 2021-000455-39: Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

Recruiting
2
60
Europe
LTX-109 gel, 3%, Placebo gel
Pharma Holdings AS, CTC Clinical Trial Consultants AB
COVID-19
02/22
05/22
2022-001938-11: A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus

Not yet recruiting
2
27
Europe
LTX-109 Hydrogel 3% w/w, Gel
Pharma Holdings AS, Pharma Holdings AS
Eradication of Staphylococcus aureus from the nose., Bacterial eradication from the nose., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
Oncopore (ruxotemitide) / Verrica
ATLAS-IT-04, NCT03725605 / 2017-002877-20: LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma

Completed
2
6
Europe
LTX-315 and TILs
Lytix Biopharma AS, Herlev Hospital
Soft Tissue Sarcoma
07/21
10/21
VP-315-201, NCT05188729: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Completed
2
92
US
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Verrica Pharmaceuticals Inc., Instat Clinical Research, HeartcoR Solutions, Myonex, Vial Health Technology, Inc, OncoBay Clinical, Q2 Solutions, Canfield Scientific, Veristat
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
04/24
04/24
NeoLIPA, NCT06651151: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

Recruiting
2
27
Europe
LTX-315 + pembrolizumab
Oslo University Hospital, Lytix Biopharma AS
Melanoma Stage IIIB-IV
05/26
05/31
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
DTT-304 / Lytix
No trials found

Download Options